Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.

Abstract:

:Intra-arterial (IA) therapies for hepatocellular carcinoma (HCC) are considered palliative and should be offered to patients with intermediate-stage multinodular disease and with sufficient liver reserve. They include transarterial chemoembolization (TACE) or bland embolization, transarterial chemotherapy, and transarterial radioembolization. While transarterial therapy is now a validated treatment for unresectable HCC, there is still controversy as to which type is the optimal procedure. This is mainly due to the lack of standardization. Combining local therapies or IA therapies with systemic targeted therapies might prove more effective strategies in the future. In this article, we review transarterial therapies and critically comment on their clinical applications.

journal_name

Semin Oncol

journal_title

Seminars in oncology

authors

Tsochatzis EA,Germani G,Burroughs AK

doi

10.1053/j.seminoncol.2010.03.007

subject

Has Abstract

pub_date

2010-04-01 00:00:00

pages

89-93

issue

2

eissn

0093-7754

issn

1532-8708

pii

S0093-7754(10)00031-X

journal_volume

37

pub_type

杂志文章,评审
  • Single agents in the second-line treatment of non-small cell lung cancer.

    abstract::The options available to patients with advanced non-small cell lung cancer (NSCLC) resistant or refractory to first-line chemotherapy are very limited. The older-generation drugs (etoposide, vindesine, epirubicin, and cisplatin) that are active against previously untreated NSCLC do not achieve a response rate greater ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Belani CP

    更新日期:1998-06-01 00:00:00

  • Advances in the biology of multiple myeloma: therapeutic applications.

    abstract::Recent advances in the biology of multiple myeloma cell growth and survival have suggested new avenues for treatment and potential cure of this disease. Adhesion molecules on the myeloma cell surface mediate their localization in the bone marrow via binding to extracellular matrix proteins and stromal cells. Stromal c...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Anderson K

    更新日期:1999-10-01 00:00:00

  • Preclinical experience with docetaxel in gastrointestinal cancers.

    abstract::Docetaxel is a semisynthetic taxane that acts primarily by promoting microtubule assembly and preventing the depolymerization of assembled microtubules, thereby inducing mitotic block and inhibition of cell proliferation. This agent also induces apoptosis and appears to prevent angiogenesis. Although docetaxel has sho...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.04.002

    authors: Bekaii-Saab TS,Villalona-Calero MA

    更新日期:2005-04-01 00:00:00

  • Ethical and legal aspects of cancer genetic testing.

    abstract::As a result of the increasing effectiveness of cancer screening and preventive interventions, ethical issues, as well as legal liabilities, are increasingly associated with cancer genetic testing. These issues include the possible "duty to warn" relatives of inherited cancer risk, the appropriateness of testing of chi...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.07.007

    authors: Offit K,Thom P

    更新日期:2007-10-01 00:00:00

  • Sequencing therapy in metastatic renal cell cancer.

    abstract::The sequencing of targeted therapy is well established in metastatic renal cancer. Switching between different vascular endothelial growth factor (VEGF)-targeted therapies or VEGF-targeted therapies and mammalian target of rapamycin (mTOR) inhibitors are both of proven benefit. The optimal sequence remains unclear. Un...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2013.05.002

    authors: Escudier B,Gore M

    更新日期:2013-08-01 00:00:00

  • Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study.

    abstract::This phase I trial was designed to determine the maximum tolerated dose of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a 3-hour infusion in combination with carboplatin (400 mg/m2) as first-line chemotherapy for stage IIIC/IV ovarian adenocarcinoma. After premedication, paclitaxel was infu...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lhommé C,Kerbrat P,Lejeune C,Guastalla JP,Fumoleau P,Goupil A,Héron JF,Cassin MA,Pruvot I,Soares JA,Chazard M

    更新日期:1996-10-01 00:00:00

  • Vascular toxicity of antineoplastic agents.

    abstract::Among the various deleterious effects of cancer chemotherapy, vascular toxicity is the least well recognized. This lack of recognition may be because the vasculotoxic phenomena are not unique to antineoplastic agents, can occur in patients without exposure to these agents, and the fact cancer itself may produce a hype...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2005.11.006

    authors: Shahab N,Haider S,Doll DC

    更新日期:2006-02-01 00:00:00

  • Evolving concepts in the systemic drug therapy of breast cancer.

    abstract::Experimental and clinical observations of the proliferation of cancer cells and their responses to cytotoxic drugs already have had an impact on the design of anticancer therapies and it is possible that further understanding of the natural history of tumors will enable better treatments to be developed. This review a...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Norton L

    更新日期:1997-08-01 00:00:00

  • Pemetrexed in the treatment of non-small cell lung cancer.

    abstract::A large meta-analysis showed that chemotherapy results in significant prolongation of survival for patients with non-small cell lung cancer (NSCLC). Pemetrexed is a new multitargeted antifolate chemotherapeutic agent that has shown activity in NSCLC and appears to be similar to the third-generation antitumor agents cu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/sonc.2002.37470

    authors: Shepherd FA

    更新日期:2002-12-01 00:00:00

  • Epidemiology of acute myelogenous leukemia.

    abstract::The epidemiologic literature suggests that environmental exposures, familial susceptibility, and cytogenetic changes affect AML risk in childhood and adulthood. Unfortunately, many studies are limited by inadequate sample sizes, imprecise case definition, or inadequate exposure measurement. Few studies have singled ou...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Sandler DP

    更新日期:1987-12-01 00:00:00

  • Central nervous system disease in hematologic malignancies: historical perspective and practical applications.

    abstract::Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2009.05.002

    authors: Pui CH,Thiel E

    更新日期:2009-08-01 00:00:00

  • Practical aspects of delivering hereditary cancer risk counseling.

    abstract::The primary element involved in the practical delivery of hereditary cancer risk counseling is the development of a cancer genetics service. This service should involve a multidisciplinary core of specialists, aim to identify at-risk individuals and their families, and provide comprehensive genetic counseling with the...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2007.07.003

    authors: DeMarco TA,Smith KL,Nusbaum RH,Peshkin BN,Schwartz MD,Isaacs C

    更新日期:2007-10-01 00:00:00

  • The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.

    abstract::In recent years, several new cytotoxic agents have been investigated for the management of non-small cell lung cancer (NSCLC), including the antimetabolic gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN) and the new multitargeted antifolate pemetrexed (Alimta, Eli Lilly and Company), which are both among ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(03)00284-7

    authors: Le Chevalier T

    更新日期:2003-08-01 00:00:00

  • 5-fluorouracil/leucovorin versus capecitabine in patients with stage III colon cancer.

    abstract::Capecitabine is an orally administered fluoropyrimidine carbamate that is preferentially converted to 5-fluorouracil in tumors relative to normal tissue. Three different dosing regimens were investigated in phase I studies: continuous monotherapy, intermittent monotherapy, and intermittent therapy supplemented with le...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1016/s0093-7754(01)90251-9

    authors: Seitz JF

    更新日期:2001-02-01 00:00:00

  • The current status of toxicity protectants in cancer therapy.

    abstract::Current therapies for the treatment of malignancies are associated with significant toxicity, as chemotherapy and radiation therapy do not discriminate between normal and malignant cells. One approach to ameliorating the toxicity associated with therapy is through the use of chemoprotective agents. This article review...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Schuchter LM,Luginbuhl WE,Meropol NJ

    更新日期:1992-12-01 00:00:00

  • Radiation Therapy Oncology Group (RTOG) studies in head and neck cancer.

    abstract::Since its foundation in 1971, the RTOG has conducted a successful clinical research program in head and neck mucosal squamous cell carcinoma with 22 treatment protocols and one registry study which combined have accumulated data on over 5,500 patients. The RTOG was the first multicenter group to evaluate neoadjuvant c...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Marcial VA,Pajak TF,Kramer S,Davis LW,Stetz J,Laramore GE,Jacobs JR,Al-Sarraf M,Brady LW

    更新日期:1988-02-01 00:00:00

  • Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.

    abstract::Vinorelbine (Navelbine; Burroughs Wellcome Co, Research Triangle Park, NC; Pierre Fabre Medicament, Paris, France), a semisynthetic vinca alkaloid, and ifosfamide have each shown activity as a single agent and in various combination-chemotherapy regimens against non-small cell lung cancer. Vinorelbine usually has been...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Masters GA,Hoffman PC,Drinkard LC,Watson S,Samuels BL,Golomb HM,Vokes EE

    更新日期:1996-04-01 00:00:00

  • Prolonging remission with rituximab maintenance therapy.

    abstract::Maintenance therapy using rituximab is currently under consideration as a means of prolonging remission in patients with indolent non-Hodgkin's lymphoma. A phase II trial using rituximab as first-line therapy followed by maintenance treatment was carried out in patients with previously untreated indolent non-Hodgkin's...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Hainsworth JD

    更新日期:2004-02-01 00:00:00

  • The human interferon-alpha species and hybrid proteins.

    abstract::Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Pestka S

    更新日期:1997-06-01 00:00:00

  • VP-16 and cisplatin in the treatment of non-small-cell lung cancer.

    abstract::The EORTC Lung Cancer Working Party investigated the effects of combination therapy with VP-16 (Ve-Pesid) and cisplatin in the treatment of non-small-cell lung cancer (NSCLC). Neither agent alone is recognized as being associated with a high rate of response in NSCLC, but the combination proved beneficial in our hands...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Klastersky J

    更新日期:1985-03-01 00:00:00

  • Common complications of advanced cancer.

    abstract::Complications due to cancer and its treatment are common and increase in incidence and severity as the disease progresses. Central nervous system complications affect 15% to 20% of patients, and up to 75% have bone metastases at some point during the disease process. Endocrine abnormalities include hypercalcemia, adre...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Nelson KA,Walsh D,Abdullah O,McDonnell F,Homsi J,Komurcu S,LeGrand SB,Zhukovsky DS

    更新日期:2000-02-01 00:00:00

  • Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.

    abstract::Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), the first taxane used in routine clinical practice, has aroused considerable interest for its high single-agent activity against breast cancer and for its novel mechanism of action. Epirubicin, the 4' epimer of doxorubicin, is another agent with a high a...

    journal_title:Seminars in oncology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Lück HJ,Thomssen C,du Bois A,Untch M,Lisboa B,Köhler G,Diergarten K

    更新日期:1997-10-01 00:00:00

  • Fatigue: definitions, mechanisms, and paradigms for study.

    abstract::Interferon-alpha (IFN-alpha) therapy is frequently associated with significant fatigue, which is often the dominant dose-limiting side effect. The fatigue associated with IFN-alpha therapy is usually dose related, worsens with continued therapy, and is associated with significant depression. Although the direct cause ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Dalakas MC,Mock V,Hawkins MJ

    更新日期:1998-02-01 00:00:00

  • Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis.

    abstract::Solid organ tumors associated with neoangiogenesis, as measured by increased microvessel density (MVD), have poorer prognoses. A similar observation of increased MVD has been made in hematologic malignancies; however, its prognostic significance remains unknown. We investigated changes in MVD in 122 newly diagnosed mu...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1016/s0093-7754(01)90025-9

    authors: Munshi NC,Wilson C

    更新日期:2001-12-01 00:00:00

  • The potential role of amifostine in conjunction with cisplatin in the treatment of locally advanced carcinoma of the cervix.

    abstract::The treatment of locally advanced carcinoma of the cervix with radiation therapy as a single modality is inadequate, specifically for stage III and IVA disease. While chemotherapy as single-modality therapy is ineffective in advanced cervical cancer, there is some evidence of efficacy when used in combination with rad...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Wadler S,Goldberg G,Fields A,Anderson P,Beitler JJ,Sood B,Haynes H,Runowicz C

    更新日期:1996-08-01 00:00:00

  • Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.

    abstract::The medical treatment of squamous cell cervical carcinoma is receiving increasing attention. Cisplatin and ifosfamide are known effective drugs. Paclitaxel has been tested with interesting results in cervical cancer. We evaluated the toxic effects and the antitumor activity of a multiagent regimen that included paclit...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:

    authors: Zanetta G,Fei F,Mangioni C

    更新日期:2000-02-01 00:00:00

  • Inflammatory breast cancer: patient advocate view.

    abstract::Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer, often presenting with distant metastasis. While controversy exists regarding the actual incidence of the disease, there is agreement that IBC causes a disproportionate number of breast cancer deaths. Those with typical IBC symptoms face a h...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:10.1053/j.seminoncol.2007.11.011

    authors: Mason G,Johnson O

    更新日期:2008-02-01 00:00:00

  • Adjuvant chemotherapy for breast cancer: an update.

    abstract::Adjuvant chemotherapy in breast cancer has clearly been shown to reduce mortality. The benefits extend to pre- and postmenopausal women and those with node-negative, node-positive, estrogen receptor (ER)-positive, and ER-negative disease. Updated data regarding chemoendocrine therapy in postmenopausal women and anthra...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1016/s0093-7754(01)90130-7

    authors: Tan AR,Swain SM

    更新日期:2001-08-01 00:00:00

  • The etiology of renal-cell carcinoma.

    abstract::Experimental renal-cell carcinoma can be induced by many different chemical carcinogens; dimethyl nitrosoamine has been most studied. The disease so induced in experimental animals closely resembles the spontaneous disease in man in histopathology, course, and other characteristics. Two agents that are probably etiolo...

    journal_title:Seminars in oncology

    pub_type: 杂志文章

    doi:

    authors: Outzen HC,Maguire HC Jr

    更新日期:1983-12-01 00:00:00

  • Management of postmenopausal symptoms in breast cancer survivors.

    abstract::With the increasing numbers of breast cancers survivors, menopause, its symptoms, and its physical complications are becoming more prevalent problems in this patient population. Hormonal replacement, which has been the cornerstone therapy of menopausal related symptoms for decades, recently has been shown to increase ...

    journal_title:Seminars in oncology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminoncol.2006.08.010

    authors: Bruno D,Feeney KJ

    更新日期:2006-12-01 00:00:00